REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 122 filers reported holding REATA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,430,000 | -74.8% | 54,226 | -3.9% | 0.00% | -75.0% |
| Q3 2021 | $5,680,000 | -28.9% | 56,455 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $7,990,000 | -11.9% | 56,455 | -37.9% | 0.01% | -14.3% |
| Q1 2021 | $9,065,000 | +42.6% | 90,923 | +76.8% | 0.01% | +40.0% |
| Q4 2020 | $6,358,000 | +29.3% | 51,431 | +1.9% | 0.01% | +25.0% |
| Q3 2020 | $4,918,000 | -40.6% | 50,484 | -4.9% | 0.00% | -50.0% |
| Q2 2020 | $8,282,000 | +13.5% | 53,081 | +5.0% | 0.01% | -11.1% |
| Q1 2020 | $7,300,000 | -49.4% | 50,577 | -28.3% | 0.01% | -30.8% |
| Q4 2019 | $14,422,000 | +384.0% | 70,547 | +90.1% | 0.01% | +333.3% |
| Q3 2019 | $2,980,000 | -3.5% | 37,119 | +13.4% | 0.00% | -25.0% |
| Q2 2019 | $3,089,000 | +9.5% | 32,735 | -0.8% | 0.00% | +33.3% |
| Q1 2019 | $2,821,000 | +76.4% | 33,001 | +15.8% | 0.00% | +50.0% |
| Q4 2018 | $1,599,000 | +459.1% | 28,503 | +713.7% | 0.00% | – |
| Q3 2018 | $286,000 | – | 3,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
| Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
| Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
| MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
| Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
| Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
| Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
| AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |